drugset / Trial / NCT03641560

A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

NCT03641560

Phase 4 Completed 52 enrolled Astellas Pharma Inc
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to evaluate the safety and tolerability of enzalutamide in Indian patients with progressive mCRPC previously treated with docetaxel-based chemotherapy. This study also evaluated the effect of enzalutamide on prostate-specific antigen (PSA).

Timeline

Start
2018-09-19
Primary completion
2024-02-20
Completion
2024-02-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Enzalutamide Other / unclassified 160 mg Oral

Indications